Rafael Holdings, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (RFL) on July 14, 2025. The report details corporate governance changes, specifically the election of a new director and amendments to the company's bylaws. CycloTherapeutics, LLC ("Cyclo") is identified as a wholly-owned subsidiary of the Company as of March 2025.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific severance agreement:
- Severance Payment: $852,168 to be paid in thirty-six semi-monthly installments.
- Equity Vesting: Continued vesting of outstanding and unvested equity for the departing executive, contingent on continued service as a service provider.
Material Changes
The primary material change reported is the transition of N. Scott Fine from Chief Executive Officer of CycloTherapeutics, LLC to an ex-officio (non-voting) director of Rafael Holdings, Inc. effective July 14, 2025. Mr. Fine will resign as CEO of Cyclo effective July 31, 2025. Additionally, the Board adopted the Fourth Amended and Restated By-Laws to authorize the position of vice chairman and the inclusion of ex-officio directors.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The document focuses strictly on the execution of the General Release Agreement with Mr. Fine and the administrative update to the By-Laws. No unusual items or contingencies beyond the executive transition were disclosed.
Investor Verification Checklist
- Verify the terms of the General Release Agreement regarding the $852,168 severance payment schedule.
- Confirm the effective date of N. Scott Fine's resignation as CEO of CycloTherapeutics, LLC (July 31, 2025).
- Review the attached Fourth Amended and Restated By-Laws (Exhibit 99.1) for specific changes to Articles III, IV, and IX.
- Check subsequent filings for the appointment of a new CEO for CycloTherapeutics, LLC.